TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori
Brief Summary: The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Sequential therapy for 14 days | Arm Label: Group B: Sequential therapy for 10 days; Type: EXPERIMENTAL; Interventions: Drug: Sequential therapy for 10 days | Arm Label: Group C: Triple therapy for 14 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triple therapy for 14 days | Intervention Type: DRUG; Name: Sequential therapy for 14 days; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Sequential therapy for 10 days; Assigned to Arm(s): Group B: Sequential therapy for 10 days | Intervention Type: DRUG; Name: Triple therapy for 14 days; Assigned to Arm(s): Group C: Triple therapy for 14 days
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: PACx14 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: PACMx5 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: PAx5/PCMx5 | Intervention Type: DRUG; Name: PACx14; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: PACMx5; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: PAx5/PCMx5; Assigned to Arm(s): Arm 3
C: Intervention Type: DRUG; Name: Placebo amoxicillin pantoprazole clarithromycin tinidazole; Assigned to Arm(s): N/A
D: Arm Label: 7-day quadruple therapy; Type: EXPERIMENTAL; Interventions: Drug: 7-day quadruple therapy | Arm Label: 10-day sequential therapy; Type: EXPERIMENTAL; Interventions: Drug: 10-day sequential therapy | Arm Label: 7-day standard triple therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: 7-day standard triple therapy | Intervention Type: DRUG; Name: 7-day quadruple therapy; Assigned to Arm(s): 7-day quadruple therapy | Intervention Type: DRUG; Name: 10-day sequential therapy; Assigned to Arm(s): 10-day sequential therapy | Intervention Type: DRUG; Name: 7-day standard triple therapy; Assigned to Arm(s): 7-day standard triple therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain
Brief Summary: The aim of the study is to evaluate and compare the effects of high-intensity (deadlift) versus low-intensity motor control exercises on selfrated pain, function and symptoms on patients with peripherally mediated pain


Options:
A: Arm Label: Game Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Game | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Game; Assigned to Arm(s): Game Condition
B: Arm Label: BB; Type: ACTIVE_COMPARATOR; Interventions: Other: Mild, Other: Mild vs. NC | Arm Label: BB+A; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Mild, Other: Mild vs. NC, Other: Moderate vs. NC | Arm Label: DBC; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: PMU; Type: EXPERIMENTAL; Interventions: Other: Moderate, Other: Moderate vs. NC | Arm Label: NC; Type: PLACEBO_COMPARATOR; Interventions: Other: Mild vs. NC, Other: Moderate vs. NC | Intervention Type: OTHER; Name: Moderate; Assigned to Arm(s): BB+A, DBC, PMU | Intervention Type: OTHER; Name: Mild; Assigned to Arm(s): BB, BB+A | Intervention Type: OTHER; Name: Mild vs. NC; Assigned to Arm(s): BB, BB+A, NC | Intervention Type: OTHER; Name: Moderate vs. NC; Assigned to Arm(s): BB+A, DBC, NC, PMU
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: McKenzie method; Type: EXPERIMENTAL; Interventions: Other: McKenzie method | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: McKenzie method; Assigned to Arm(s): McKenzie method
D: Intervention Type: PROCEDURE; Name: High intensity motor control exercise (deadlift); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Low intensity motor control exercise; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain
Brief Summary: The aim of the study is to evaluate and compare the effects of high-intensity (deadlift) versus low-intensity motor control exercises on selfrated pain, function and symptoms on patients with peripherally mediated pain


Options:
A: Intervention Type: PROCEDURE; Name: High intensity motor control exercise (deadlift); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Low intensity motor control exercise; Assigned to Arm(s): N/A
B: Arm Label: Core stabilization and psychosocial education; Type: EXPERIMENTAL; Interventions: Behavioral: Core stabilization and psychosocial education | Arm Label: Core stabilization exercise only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core stabilization exercise only | Arm Label: Psychosocial education class only.; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychosocial education class only | Arm Label: Traditional Army training; Type: OTHER; Interventions: Behavioral: Traditional Army training | Intervention Type: BEHAVIORAL; Name: Traditional Army training; Assigned to Arm(s): Traditional Army training | Intervention Type: BEHAVIORAL; Name: Core stabilization exercise only; Assigned to Arm(s): Core stabilization exercise only | Intervention Type: BEHAVIORAL; Name: Psychosocial education class only; Assigned to Arm(s): Psychosocial education class only. | Intervention Type: BEHAVIORAL; Name: Core stabilization and psychosocial education; Assigned to Arm(s): Core stabilization and psychosocial education
C: Arm Label: Stabilization group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Arm Label: Strengthening group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Arm Label: Stretching group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Intervention Type: OTHER; Name: Stabilization , strengthening and stretching; Assigned to Arm(s): Stabilization group, Strengthening group, Stretching group
D: Arm Label: TrA exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Isolated Transversus abdominis (TrA) exercise | Arm Label: sling exercise; Type: EXPERIMENTAL; Interventions: Behavioral: sling exercise | Arm Label: group exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: group exercise | Intervention Type: BEHAVIORAL; Name: Isolated Transversus abdominis (TrA) exercise; Assigned to Arm(s): TrA exercise | Intervention Type: BEHAVIORAL; Name: sling exercise; Assigned to Arm(s): sling exercise | Intervention Type: BEHAVIORAL; Name: group exercise; Assigned to Arm(s): group exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain
Brief Summary: The aim of the study is to evaluate and compare the effects of high-intensity (deadlift) versus low-intensity motor control exercises on selfrated pain, function and symptoms on patients with peripherally mediated pain


Options:
A: Arm Label: Stabilization group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Arm Label: Strengthening group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Arm Label: Stretching group; Type: EXPERIMENTAL; Interventions: Other: Stabilization , strengthening and stretching | Intervention Type: OTHER; Name: Stabilization , strengthening and stretching; Assigned to Arm(s): Stabilization group, Strengthening group, Stretching group
B: Intervention Type: PROCEDURE; Name: Chiropractic Spinal Manipulation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A
C: Arm Label: Treatment based on Movement System Impairment based model; Type: EXPERIMENTAL; Interventions: Other: Treatment based on Movement System Impairment model | Arm Label: General exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: General exercise | Intervention Type: OTHER; Name: Treatment based on Movement System Impairment model; Assigned to Arm(s): Treatment based on Movement System Impairment based model | Intervention Type: OTHER; Name: General exercise; Assigned to Arm(s): General exercise
D: Intervention Type: PROCEDURE; Name: High intensity motor control exercise (deadlift); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Low intensity motor control exercise; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Brief Summary: To determine the effect of daily administration of 40 mgms simvastatin taken for at least 12 months (range 12-36 months) on the frequency of exacerbations of chronic obstructive lung disease (COPD) in patients with moderate to severe COPD who are prone to exacerbations and do not have other indications for statin treatment.


Options:
A: Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Arm Label: Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: simvastatin, placebo | Arm Label: B1-6-12; Type: PLACEBO_COMPARATOR; Interventions: Drug: simvastatin, placebo | Intervention Type: DRUG; Name: simvastatin, placebo; Assigned to Arm(s): B1-6-12, Simvastatin
D: Arm Label: fluticasone furoate/umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI) | Arm Label: umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Intervention Type: DRUG; Name: fluticasone furoate (FF); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: vilanterol (VI); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol, umeclidinium bromide/vilanterol | Intervention Type: DRUG; Name: umeclidinium bromide (UMEC); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, umeclidinium bromide/vilanterol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Erythritol and Xylitol on Dental Caries Prevention in Children
Brief Summary: This study aims at demonstrating the effect of erythritol and xylitol lozenges on preventing the new caries lesions and the possible remineralization effect of both polyols on incipient caries lesions.


Options:
A: Arm Label: A, observation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: A, erythritol | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: C, sorbitol | Intervention Type: DIETARY_SUPPLEMENT; Name: A, erythritol; Assigned to Arm(s): A, observation | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: C, sorbitol; Assigned to Arm(s): C
B: Arm Label: xylitol lozenge; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol | Arm Label: inactive lozenge; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: inactive lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol; Assigned to Arm(s): xylitol lozenge | Intervention Type: DIETARY_SUPPLEMENT; Name: inactive lozenge; Assigned to Arm(s): inactive lozenge
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sorbitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Xylitol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Xylitol + BB12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Sorbitol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol + BB12; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Xylitol; Assigned to Arm(s): 2
D: Arm Label: xylitol wipe; Type: EXPERIMENTAL; Interventions: Dietary Supplement: xylitol wipe | Arm Label: placebo wipe; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: xylitol wipe; Assigned to Arm(s): xylitol wipe | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo wipe; Assigned to Arm(s): placebo wipe

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Two Amino Acid Solutions on Blood Amino Acid Levels and Frequency of Cholestasis in Neonates
Brief Summary: The purpose of this study is to analyze if the infants who received Primene solution, have lower serum levels of methionine and cysteine and higher serum levels of taurine, we also analyze if the infants who received Primene solution develop TPN-associated cholestasis in a smaller proportion than those who received Trophamine solution.


Options:
A: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
B: Arm Label: Trophamine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primene 10% from Baxter; Type: EXPERIMENTAL; Interventions: Other: Primene 10 % from Baxter | Intervention Type: OTHER; Name: Primene 10 % from Baxter; Assigned to Arm(s): Primene 10% from Baxter
C: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: New Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: New Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
D: Arm Label: Control Study Formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Study Formula | Arm Label: Experimental Study Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Study Formula | Intervention Type: OTHER; Name: Control Study Formula; Assigned to Arm(s): Control Study Formula | Intervention Type: OTHER; Name: Experimental Study Formula; Assigned to Arm(s): Experimental Study Formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: South Danish Hypertension and Diabetes Study
Brief Summary: The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.


Options:
A: Arm Label: addition of spironolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): addition of spironolactone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone, Drug: Standard care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard care | Arm Label: Observational; Type: OTHER; Interventions: Drug: Standard care | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard care; Assigned to Arm(s): Observational, Placebo, Spironolactone
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 5 | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Arm 6
D: Intervention Type: DRUG; Name: losartan 100 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: spironolactone 25 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo once orally once daily; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants
Brief Summary: Hypothesis to be Tested:

Since the first description of intravenous alimentation over half a century ago, parenteral nutrition (PN) has become a common nutritional intervention for conditions characterized by inability to tolerate enteral feeds such as Short Bowel Syndrome, Chronic Intestinal Pseudoobstruction, Microvillus Inclusion Disease, Crohn's disease, multi-organ failure and prematurity. Parenteral Nutrition-Associated Liver Disease (PNALD) encompasses a spectrum of disease including cholestasis, hepatitis, steatosis and gallbladder sludge/stones which may progress to liver cirrhosis and even failure.

There is a direct correlation between duration of parenteral nutrition and development of cholestasis in infants. There is evidence in animals and humans that cycling of parental nutrition, defined as infusing nutrients over a time period shorter than 24 hours, reduces cholestasis. There is also data that premature infants with gestational age (GA) \< 32 weeks and birth weight \<1500g, as well as infants with congenital anomalies of the gastrointestinal tract, are among those at highest risk of developing Parenteral Nutrition-Associated Cholestasis (PNAC).

We therefore hypothesize that infants with gestational age (GA) \<32 weeks and birth weight (BW) between \<1500g, or with congenital anomaly of the gastrointestinal tract regardless of GA or BW, receiving PN over a period of 20 hours will have a decrease severity of PNAC, demonstrated by a lower peak direct bilirubin, compared to a similar control population receiving standard 24 hour infusion.


Options:
A: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: New Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: New Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
B: Arm Label: Active Comparator; Type: EXPERIMENTAL; Interventions: Drug: Carbaglu | Arm Label: Placebo Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Carbaglu; Assigned to Arm(s): Active Comparator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator
C: Arm Label: Amix; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amix | Intervention Type: DIETARY_SUPPLEMENT; Name: Amix; Assigned to Arm(s): Amix
D: Arm Label: Cycling Parenteral Nutrition; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Parenteral Nutrition | Arm Label: Continuous Parenteral Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Parenteral Nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: Parenteral Nutrition; Assigned to Arm(s): Continuous Parenteral Nutrition, Cycling Parenteral Nutrition

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS
Brief Summary: The proposed study will evaluate whether the combination of VELCADE, Thalidomide , Melphalan and Prednisone (V-MPT), as induction treatment for newly diagnosed elderly MM patients, improves outcomes compared to the combination VELCADE-MP.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VELCADE Administered by subcutaneous injection | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: VELCADE Administered by intravenous infusion | Intervention Type: DRUG; Name: VELCADE Administered by subcutaneous injection; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: VELCADE Administered by intravenous infusion; Assigned to Arm(s): 2
B: Arm Label: VTD; Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Arm Label: TD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Thalidomide, Drug: Dexamethasone, Procedure: Peripheral Blood Stem Cell (PBSC) collection, Procedure: First Autologous Transplantation, Procedure: Second Autologous Transplantation | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): VTD | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): TD, VTD | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell (PBSC) collection; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: First Autologous Transplantation; Assigned to Arm(s): TD, VTD | Intervention Type: PROCEDURE; Name: Second Autologous Transplantation; Assigned to Arm(s): TD, VTD
C: Arm Label: carfilzomib (A0); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Arm Label: carfilzomib (A1); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A0) | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A1)
D: Arm Label: Arm A: VMPT; Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Melphalan, Prednisone, Thalidomide | Arm Label: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bortezomib, Melphalan, Prednisone | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone, Thalidomide; Assigned to Arm(s): Arm A: VMPT | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone; Assigned to Arm(s): VMP

Answer: D